Fig. 3From: Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairmentEffect of pramipexole (PPX) versus ropinirole (RPR) on cued recall according to patients’ dopamine agonist on entry to the studyBack to article page